StockNews.AI
TIL
StockNews.AI
88 days

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

1. Instil Bio and ImmuneOnco to host investor breakfast on May 31, 2025. 2. Discussion will focus on PD-(L)1xVEGF bispecific antibodies and clinical updates. 3. Instil's lead asset, AXN-2510, targets multiple solid tumors. 4. ImmuneOnco has multiple assets in development, with one in phase III. 5. Key opinion leaders will present insights during the event.

4m saved
Insight
Article

FAQ

Why Bullish?

The joint event emphasizes the potential of Instil's therapies, likely generating positive investor sentiment.

How important is it?

The focused event on cancer therapies can drive immediate interest among investors and analysts.

Why Short Term?

Investor interest may spike around the event but will stabilize post-event.

Related Companies

IMOCFVRTXMRUSBMY
May 23, 2025 07:00 ET  | Source: Instil Bio DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center. Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates from Instil and ImmuneOnco. Investors and analysts interested in attending should register by emailing their contact information to reserve seating to investorrelations@instilbio.com. About ImmuneOncoImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers, autoimmune diseases and metabolic diseases. With 10+ assets all originated in-house and the most advanced asset in phase III right now, ImmuneOnco is pursuing innovative therapies to improve patients’ health. For more information visit www.immuneonco.com. About Instil BioInstil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visit www.instilbio.com. Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts:Investor Relations:1-972-499-3350investorrelations@instilbio.comwww.instilbio.com

Related News